Log in to search using one of your social media accounts:

 

N.M. Paramedic Helps Young Cancer Patient With His 'Bucket List'
RIO RANCHO, N.M. (KRQE) –They met only once, but a strong bond ties a local paramedic to her former patient. Now, she’s hoping to help grant a big wish for a child battling cancer. Paramedic Jennifer Saiz is a cancer survivor but her patient is still in the fight. She says his joyful spirit touched her so much, she wanted to help check off an item on his bucket list. At the Dimas’ household, there are plenty of presents wrapped under the tree. But what’s on 10-year-old Elijah’s Christmas list can’t be tied with a bow. “Visit the Pokémon center in Japan, get Nickelodeon...
Source: JEMS Administration and Leadership - December 13, 2017 Category: Emergency Medicine Authors: Francesca Washington, KRQE Tags: News Videos Administration and Leadership Source Type: news

Uterine Cancer Sarcoma
Uterine Cancer: Sarcoma (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - November 29, 2017 Category: General Medicine Source Type: news

How precision medicine turned Jesus ’ unique tumor into an operable one
On a hot, August day in a Boston park, Jesus Apolinaris Cruz cooled off with a water squirt gun fight with his mother and sister. As he nimbly ran and dodged their aim, he twisted around to sneak shots of water back in their direction.  Peals of laughter rang out from the group as Jesus landed a jet of water on his sister. It’s hard to imagine that just weeks earlier, Jesus, 13, had undergone surgery near his hip to remove an unclassified tumor, so-described because it couldn’t be categorized as any specific kind of cancer. “We had been praying for months that the surgery would go well,” says M...
Source: Thrive, Children's Hospital Boston - November 13, 2017 Category: Pediatrics Authors: Kat J. McAlpine Tags: Our Patients’ Stories Research and Innovation Cancer clinical trials Dana-Farber/Boston Children's Dr. Katherine Janeway Dr. Steven DuBois Experimental Therapeutics Program pediatric cancer precision medicine sarcoma Solid Tumors C Source Type: news

PharmaMar presents positive results from a Phase II study of PM1183 in Ewing's sarcoma
(Pharmamar) PharmaMar (MSE:PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing ´ s sarcoma at the Connective Tissue Oncology Society ´ s (CTOS) International Congress that took place in Hawaii from the 8th to the 11th of November. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2017 Category: Cancer & Oncology Source Type: news

Cancer treatment response may be affected by gut bacteria
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - November 3, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Two classes of GGAA-microsatellites in a Ewing sarcoma context
(Nationwide Children's Hospital) In a study published in PLOS ONE, researchers describe two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma. Ewing sarcoma is the second most common pediatric bone malignancy. It is initiated by chromosomal translocation t(11;22)(q24;q12), which creates the fusion protein and oncogenic driver EWS/FLI. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2017 Category: Cancer & Oncology Source Type: news

Three of the most deadly cancers get critical funding for research
Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the deadliest forms of cancer: glioblastoma (brain cancer), sarcoma (bone cancer) and ovarian cancer. Three scientists have received $1.3 million in critical funding from the Alliance for Cancer Gene Therapy (ACGT), the nation's only nonprofit dedicated exclusively to cell and gene therapies for cancer. (Source: World Pharma News)
Source: World Pharma News - October 18, 2017 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Three of the most deadly cancers get critical funding for research
(Alliance for Cancer Gene Therapy) Three of the most deadly cancers -- glioblastoma, sarcoma and ovarian -- get critical funding for clinical trials from Alliance for Cancer Gene Therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2017 Category: Cancer & Oncology Source Type: news

Living With Cancer: Cancer Humor
Cracking up may be a better option than breaking down, or so three recent books by young people with cancer suggest. (Source: NYT Health)
Source: NYT Health - October 12, 2017 Category: Consumer Health News Authors: SUSAN GUBAR Tags: Breast Cancer Books and Literature Ewing's Sarcoma (Disease) Comedy and Humor Riggs, Nina (1977-2017) Harrison, Teva (1976- ) Ritvo, Max (1990-2016) Source Type: news

Two agents deliver knockout punches to Ewing sarcoma
(Georgetown University Medical Center) When combined with an already FDA-approved chemotherapy, a novel agent developed by researchers at Georgetown Lombardi Comprehensive Cancer Center, appears to halt the ability of Ewing sarcoma to grow and progress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2017 Category: Cancer & Oncology Source Type: news

Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewings sarcoma
Ewing’s sarcoma (ES) is a rare and highly malignant cancer that grows in the bones or surrounding tissues mostly affecting adolescents and young adults. A chimeric fusion between the RNA binding protein EWS and the ETS family transcription factor FLI1 (EWS-FLI1), which is generated from a chromosomal translocation, is implicated in driving most ES cases by modulation of transcription and alternative splicing. The small-molecule YK-4-279 inhibits EWS-FLI1 function and induces apoptosis in ES cells. We aimed to identify both the underlying mechanism of the drug and potential combination therapies that might enhance its...
Source: Signal Transduction Knowledge Environment - October 3, 2017 Category: Science Authors: Zöllner, S. K., Selvanathan, S. P., Graham, G. T., Commins, R. M. T., Hong, S. H., Moseley, E., Parks, S., Haladyna, J. N., Erkizan, H. V., Dirksen, U., Hogarty, M. D., Üren, A., Toretsky, J. A. Tags: STKE Research Articles Source Type: news

Male hormones may promote infection by virus that causes Kaposi's sarcoma
(PLOS) Male hormones may facilitate infection with a virus that can cause a type of cancer known as Kaposi's sarcoma. This finding, published in PLOS Pathogens by Ke Lan's group of the State Key Laboratory of Virology, Wuhan University, China, could help explain why men have an increased risk of developing Kaposi's sarcoma. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 28, 2017 Category: Infectious Diseases Source Type: news

First-Line Doxorubicin for Advanced Sarcoma, Not Combo? First-Line Doxorubicin for Advanced Sarcoma, Not Combo?
Doxorubicin should remain first-line therapy for patients with soft-tissue sarcoma, conclude trialists who compared it with a gemcitabine and docetaxel combination.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 27, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New clinical trial explores combining immunotherapy and radiation for sarcoma patients
(University of Maryland Medical Center) University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to destroy the main tumor as well as leftover microscopic cancer cells that may seed other tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

UCLA starts Phase I stem cell trial for cancers with NY-ESO-1 tumour marker
The University of California, Los Angeles (UCLA) has started a Phase I clinical trial to evaluate new genetically engineered blood-forming stem cells to treat cancers such as melanoma and sarcoma with a specific tumour marker called NY-ESO-1. (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Synovial sarcoma: Treatment, diagnosis, and research
What is synovial sarcoma, what are the symptoms of synovial sarcoma, and how is it diagnosed? What causes synovial sarcoma and what is the outlook? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 4, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Which Cancers Secondary to Kaposi Sarcoma Are Emerging in the HAART Era? Which Cancers Secondary to Kaposi Sarcoma Are Emerging in the HAART Era?
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

ART Era Has Changed Secondary Cancers After Kaposi Sarcoma
Certain cancers - - ALL and cancers of the tongue, penis - - becoming more common (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 25, 2017 Category: Cancer & Oncology Tags: Dermatology, Infections, AIDS, Internal Medicine, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Metastatic Synovial Sarcoma of Lung Mimicking PE and DVT Metastatic Synovial Sarcoma of Lung Mimicking PE and DVT
What can we learn from this case of metastatic synovial sarcoma initially misdiagnosed as deep venous thrombosis?Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

NantCell takes on troubled CytRx chemotherapeutic
NantCell, one of controversial biotech entrepreneur Patrick Soon-Shiong’s many businesses, said last week that it inked a deal to acquire CytRx‘s (NSDQ:CYTR) aldoxorubicin cancer drug. The compound has faced several obstacles in clinical trials, including when it missed the primary endpoint of a late-stage clinical trial, failing to help patients with second-line soft tissue sarcoma in a significant way compared to a control therapy. Get the full story at our sister site, Drug Delivery Business News. The post NantCell takes on troubled CytRx chemotherapeutic appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Biotech Drug-Device Combinations Mergers & Acquisitions Oncology Pharmaceuticals Wall Street Beat cytrx nantcell Source Type: news

Leicester cancer boy heading home after treatment in US
Alex Goodwin, from Rugby, England, was diagnosed with Ewing's Sarcoma last year after months of agony in his joints and muscles. He finished treatment earlier this month and is headed home in August. (Source: the Mail online | Health)
Source: the Mail online | Health - July 28, 2017 Category: Consumer Health News Source Type: news

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma
In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin. (Source: CancerNetwork)
Source: CancerNetwork - July 22, 2017 Category: Cancer & Oncology Authors: Sant P. Chawla, MD Tags: Sarcoma Source Type: news

Activity of PD-1 Inhibitor Limited in Soft-Tissue Sarcomas
Treatment with the PD-1 inhibitor pembrolizumab plus metronomic cyclophosphamide had limited activity in patients with soft-tissue sarcomas and gastrointestinal stromal tumors. (Source: CancerNetwork)
Source: CancerNetwork - July 11, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Sarcoma Source Type: news

Synovial Sarcoma man left with half a face after cancer
WARNING GRAPHIC CONTENT: Tim McGrath, 38, from Michigan, was diagnosed with Synovial Sarcoma - an extremely rare form of soft tissue cancer - leaving him with a grape fruit-sized tumour. (Source: the Mail online | Health)
Source: the Mail online | Health - July 7, 2017 Category: Consumer Health News Source Type: news

Coughing and constipation? You could be suffering from THIS rare whole-body cancer
COUGHING and constipation are two of the symptoms of soft tissue sarcomas - a group of rare cancers that can appear anywhere in the body. (Source: Daily Express - Health)
Source: Daily Express - Health - July 5, 2017 Category: Consumer Health News Source Type: news

David Loeb, M.D., PH.D., Named Chief of Pediatric Hematology-Oncology at the Children ’s Hospital at Montefiore and Albert Einstein College of Medicine
June 26, 2017—(BRONX, NY)—Leading pediatric oncologist and NIH-funded researcher David M. Loeb, M.D., Ph.D., has been named chief of the division of pediatric hematology, oncology, marrow and blood cell transplantation atAlbert Einstein College of Medicine and theChildren’s Hospital at Montefiore (CHAM). A noted sarcoma researcher and clinician and bone marrow transplantation specialist, Dr. Loeb will join the faculty on September 1, 2017. (Source: Einstein News)
Source: Einstein News - June 26, 2017 Category: Universities & Medical Training Source Type: news

David Loeb, M.D., Ph.D., Named Chief of Pediatric Hematology-Oncology at the Children ’s Hospital at Montefiore and Albert Einstein College of Medicine
June 26, 2017—(BRONX, NY)—Leading pediatric oncologist and NIH-funded researcher David M. Loeb, M.D., Ph.D., has been named chief of the division of pediatric hematology, oncology, marrow and blood cell transplantation atAlbert Einstein College of Medicine and theChildren’s Hospital at Montefiore (CHAM). A noted sarcoma researcher and clinician and bone marrow transplantation specialist, Dr. Loeb will join the faculty on September 1, 2017. (Source: Einstein News)
Source: Einstein News - June 26, 2017 Category: Universities & Medical Training Source Type: news

David Loeb, M.D., Ph.D., Named Chief of Pediatric Hematology-Oncology at the Children's Hospital at Montefiore and Albert Einstein College of Medicine
June 26, 2017—(BRONX, NY)—Leading pediatric oncologist and NIH-funded researcher David M. Loeb, M.D., Ph.D., has been named chief of the division of pediatric hematology, oncology, marrow and blood cell transplantation atAlbert Einstein College of Medicine and theChildren’s Hospital at Montefiore (CHAM). A noted sarcoma researcher and clinician and bone marrow transplantation specialist, Dr. Loeb will join the faculty on September 1, 2017. (Source: Einstein News)
Source: Einstein News - June 26, 2017 Category: Universities & Medical Training Source Type: news

10 Facts Women Should Know About Endometrial Cancer
The most common cancer of the reproductive organs in American women is endometrial cancer. The American Cancer Society estimates that for the year 2017, around 61,380 new cases of cancer of the body of the uterus will be diagnosed and about 10,920 women will die from cancers of the uterine body. These figures include both endometrial cancers and uterine sarcomas. Since endometrial cancer is a fairly common cancer in women, the more women know the facts about this disease, the greater their chance of knowing what symptoms to be aware of in order to have it diagnosed as early as possible, improving the likelihood of surviva...
Source: Healthy Living - The Huffington Post - June 5, 2017 Category: Consumer Health News Source Type: news

How killer cells take out tumors
The promising drug is known as F8-TNF. When injected into the bloodstream, it lures killer cells from the body's immune system towards sarcomas. The killer cells then destroy the tumours. Researchers from ETH Zurich, led by Professor Dario Neri at the Institute of Pharmaceutical Sciences, developed F8-TNF four years ago. Since then, they have been able to show that it can completely cure sarcomas in mice when combined with a chemotherapeutic agent. (Source: World Pharma News)
Source: World Pharma News - June 5, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Mixed Results with Novel Tx in Sarcoma
(MedPage Today) -- Aldodoxorubicin can't boost PFS, but promising in L-sarcomas (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 4, 2017 Category: Hematology Source Type: news

Immune responses from early study of novel sarcoma vaccine
(Fred Hutchinson Cancer Research Center) The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects.This is according to a poster to be presented June 5 at the American Society of Clinical Oncology annual meeting in Chicago. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2017 Category: Cancer & Oncology Source Type: news

Patient safety pioneer Dr. Amy Reed dies at 44
The physician who helped put an end to the 18-year gap between the FDA’s approval of laparoscopic power morcellators and the safety watchdog learning that the devices can spread malignant cancers in the abdomen, Dr. Amy Reed, died yesterday of leiomyosarcoma, according to news reports. She was 44. Power morcellators use small, rotating blades to break up large tissue masses into fragments and are commonly used to remove benign uterine fibroids in women. But if the device is used on a patient with undetected cancer, it can strew cancerous cells throughout the abdomen. Although the FDA approved morcellat...
Source: Mass Device - May 25, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Women's Health Source Type: news

A New Diagnosis of HIV and Pulmonary Kaposi's Sarcoma A New Diagnosis of HIV and Pulmonary Kaposi's Sarcoma
A case of chronic cough ultimately reveals a diagnosis of HIV infection with pulmonary Kaposi's sarcoma. How was this unusual case diagnosed?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 15, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

A protein, a 'molecular staple' and CRISPR to develop an Ewing sarcoma model
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) A team from the Spanish National Cancer Research Centre (CNIO) has optimized a system capable of generating a cellular model of Ewing sarcoma. The technique, based on CRISPR and described in the pages of Stem Cell Reports, makes it possible to generate cellular models to analyze the mechanisms underlying the origin and progression of this and other diseases, as well as the search for new treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 10, 2017 Category: International Medicine & Public Health Source Type: news

Soft Tissue Sarcoma Differences: Therapeutic Implications Soft Tissue Sarcoma Differences: Therapeutic Implications
Differences in the immunologic profiles of soft tissue sarcoma subtypes could have implications for treatment with immune checkpoint inhibitors, researchers report.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - May 4, 2017 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news

First extensive immune profile of sarcomas shows some likely susceptible to immunotherapy
(Fred Hutchinson Cancer Research Center) Some types of sarcomas elicit a greater immune response than others, which sheds light on how immunotherapy could be used for this connective-tissue cancer, according to a new study in Cancer. Photos, video available. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 2, 2017 Category: Cancer & Oncology Source Type: news

CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
Development Program Can Support Approval, No New Studies Requested NDA Submission by CytRx Being Prepared Conference Call on April 19, 2017 at 8:30 AM EDT/ 5:30 AM PDT LOS ANGELES, April 19, 2017 -- (Healthcare Sales & Marketing Network) -- CytRx... Biopharmaceuticals, Oncology, FDA CytRx, aldoxorubicin, soft tissue sarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 19, 2017 Category: Pharmaceuticals Source Type: news

MD Anderson and Lion Biotechnologies announce strategic alliance to conduct clinical trials of TILs
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian, various sarcomas, and pancreatic cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2017 Category: Cancer & Oncology Source Type: news

Girl With Cancer Receives American Girl Doll With Prosthetic Leg Like Hers
After losing her leg to cancer, a 10-year-old girl found companionship in a special doll with the same condition. In November 2016, Dylan Probe was diagnosed with a type of bone cancer called Ewing’s sarcoma. The fourth-grader had to undergo chemotherapy and on March 17, had her right leg amputated below the knee.   Throughout Dylan’s battle with cancer, photographer Sherina Welch has documented her journey in the hospital. Following the surgery, Welch decided to surprise the brave little girl with an American Girl doll that has a prosthetic leg just like hers. Welch ordered the doll from a company c...
Source: Healthy Living - The Huffington Post - April 14, 2017 Category: Consumer Health News Source Type: news

Toddler Who Lost Eye To Cancer Forms Special Bond With Toy That Looks Like Her
A 3-year-old girl who lost her eye to cancer found a special friend in a toy bunny with the same condition. Danielle Munger’s daughter Brynn was diagnosed with a rare cancer called undifferentiated sarcoma shortly after her first birthday when doctors discovered a tumor behind her left eye. As a result, she had to undergo multiple surgeries and ultimately lost her eye. Today, Brynn has been in remission for over 16 months. In honor of her third birthday in March, Danielle gave her daughter a custom-made bunny, who also has one eye. The Utah mom ordered the bunny from Jessica Sebastian of Sebastian Design. Danielle t...
Source: Healthy Living - The Huffington Post - April 10, 2017 Category: Consumer Health News Source Type: news

In 2030, the Top Cancer in HIV Patients May Be a Surprise In 2030, the Top Cancer in HIV Patients May Be a Surprise
Kaposi sarcoma is becoming a thing of the past in this population, thanks to antiretroviral therapy. A new study predicts a shift in cancers among people with HIV, who are increasingly older.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 5, 2017 Category: Infectious Diseases Tags: Hematology-Oncology News Source Type: news

Your NEJM Group Today: Kaposi's Sarcoma of the Oral Cavity / Predicting Response to Depression Treatment / Kentucky Hospitalist Opportunities (FREE)
By the Editors Here's what we chose for you from NEJM Group Today:NEJM Clinical Practice Center: Image in Clinical Medicine: A 33-year-old man presented with … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 5, 2017 Category: Primary Care Source Type: news

New drug delivery system shows promise for fighting solid tumors
A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment. Carcinomas that affect the breast, lung, prostate and colon are among these solid-tumor cancers, as are malignancies in the lymphatic system, known as lymphomas, and the much less common sarcomas that arise in connective tissue. (Source: World Pharma News)
Source: World Pharma News - April 4, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Deploying an ancient defense to kill cancer
What if your body's ancient defenses against invading bacteria could be hijacked to help kill cancer? In a small sarcoma trial, scientists have found signs of immune attack after injections of a bacteria-inspired drug. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 3, 2017 Category: Science Source Type: news

KIT Mutations Linked to Imatinib Response in GIST KIT Mutations Linked to Imatinib Response in GIST
Different KIT mutations have various associations with the response of gastrointestinal stromal tumors (GISTs) to adjuvant imatinib, according to results from a Scandinavian Sarcoma Group multicenter trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Deploying an ancient defense to kill cancer
(Fred Hutchinson Cancer Research Center) What if your body's ancient defenses against invading bacteria could be hijacked to help kill cancer? In a small sarcoma trial, Fred Hutch scientists led by Dr. Seth Pollack see signs of immune attack after injections of a bacteria-inspired drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 3, 2017 Category: Cancer & Oncology Source Type: news

' Jumonji' protein key to Ewing's sarcoma rampage
A new study pinpoints a protein that may be essential to Ewing's sarcoma metastasis -- when researchers knocked down the protein KDM3A in Ewing's sarcoma tumor cells, one of a family known as Jumonji proteins, they also inhibited the cancer's metastatic ability. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 24, 2017 Category: Science Source Type: news

'Jumonji' protein key to Ewing's sarcoma rampage
(University of Colorado Anschutz Medical Campus) A University of Colorado Cancer Center study published in the journal Oncogene pinpoints a protein that may be essential to Ewing's sarcoma metastasis -- when researchers knocked down the protein KDM3A in Ewing's sarcoma tumor cells, one of a family known as Jumonji proteins, they also inhibited the cancer's metastatic ability. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 24, 2017 Category: Cancer & Oncology Source Type: news